Potential to streamline heterologous DNA prime and NYVAC/protein boost HIV vaccine regimens in rhesus macaques by employing improved antigens

Benedikt Asbach, Alexander Kliche, Josef Köstler, Beatriz Perdiguero, Mariano Esteban, Bertram Jacobs, David C. Montefiori, Celia C. LaBranche, Nicole L. Yates, Georgia D. Tomaras, Guido Ferrari, Kathryn E. Foulds, Mario Roederer, Gary Landucci, Donald N. Forthal, Michael S. Seaman, Natalie Hawkins, Steven G. Self, Alicia Sato, Raphael Gottardo & 12 others Sanjay Phogat, James Tartaglia, Susan W. Barnett, Brian Burke, Anthony D. Cristillo, Deborah E. Weiss, Jesse Francis, Lindsey Galmin, Song Ding, Jonathan L. Heeney, Giuseppe Pantaleo, Ralf Wagner

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus vectors and combinations with DNA and protein vaccines. Earlier clinical trials (EuroVacc trials 01 to 03) evaluated the immunogenicity of HIV-1 clade C GagPolNef and gp120 antigens delivered via the poxviral vector NYVAC. These showed that a vaccination regimen including DNA-C priming prior to a NYVAC-C boost considerably enhanced vaccine-elicited immune responses compared to those with NYVAC-C alone. Moreover, responses were improved by using three as opposed to two DNA-C primes. In the present study, we assessed in nonhuman primates whether such vaccination regimens can be streamlined further by using fewer and accelerated immunizations and employing a novel generation of improved DNA-C and NYVAC-C vaccine candidates designed for higher expression levels and more balanced immune responses. Three different DNA-C prime/NYVAC-C+protein boost vaccination regimens were tested in rhesus macaques. All regimens elicited vigorous and well-balanced CD8+ and CD4+ T cell responses that were broad and polyfunctional. Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and modest antibody-dependent cell-mediated virus inhibition (ADCVI), but very low neutralization activity, were measured after the final immunizations. Overall, immune responses elicited in all three groups were very similar and of greater magnitude, breadth, and quality than those of earlier Euro- Vacc vaccines. In conclusion, these findings indicate that vaccination schemes can be simplified by using improved antigens and regimens. This may offer a more practical and affordable means to elicit potentially protective immune responses upon vaccination, especially in resource-constrained settings.

Original languageEnglish (US)
Pages (from-to)4133-4149
Number of pages17
JournalJournal of Virology
Volume90
Issue number8
DOIs
StatePublished - Apr 1 2016

Fingerprint

AIDS Vaccines
Macaca mulatta
Vaccination
vaccination
immune response
vaccines
antigens
Antigens
DNA
Proteins
proteins
Immunization
immunization
Vaccines
Poxviridae
Antibody-Dependent Cell Cytotoxicity
DNA Vaccines
antibodies
Human immunodeficiency virus 1
Protein C

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Potential to streamline heterologous DNA prime and NYVAC/protein boost HIV vaccine regimens in rhesus macaques by employing improved antigens. / Asbach, Benedikt; Kliche, Alexander; Köstler, Josef; Perdiguero, Beatriz; Esteban, Mariano; Jacobs, Bertram; Montefiori, David C.; LaBranche, Celia C.; Yates, Nicole L.; Tomaras, Georgia D.; Ferrari, Guido; Foulds, Kathryn E.; Roederer, Mario; Landucci, Gary; Forthal, Donald N.; Seaman, Michael S.; Hawkins, Natalie; Self, Steven G.; Sato, Alicia; Gottardo, Raphael; Phogat, Sanjay; Tartaglia, James; Barnett, Susan W.; Burke, Brian; Cristillo, Anthony D.; Weiss, Deborah E.; Francis, Jesse; Galmin, Lindsey; Ding, Song; Heeney, Jonathan L.; Pantaleo, Giuseppe; Wagner, Ralf.

In: Journal of Virology, Vol. 90, No. 8, 01.04.2016, p. 4133-4149.

Research output: Contribution to journalArticle

Asbach, B, Kliche, A, Köstler, J, Perdiguero, B, Esteban, M, Jacobs, B, Montefiori, DC, LaBranche, CC, Yates, NL, Tomaras, GD, Ferrari, G, Foulds, KE, Roederer, M, Landucci, G, Forthal, DN, Seaman, MS, Hawkins, N, Self, SG, Sato, A, Gottardo, R, Phogat, S, Tartaglia, J, Barnett, SW, Burke, B, Cristillo, AD, Weiss, DE, Francis, J, Galmin, L, Ding, S, Heeney, JL, Pantaleo, G & Wagner, R 2016, 'Potential to streamline heterologous DNA prime and NYVAC/protein boost HIV vaccine regimens in rhesus macaques by employing improved antigens', Journal of Virology, vol. 90, no. 8, pp. 4133-4149. https://doi.org/10.1128/JVI.03135-15
Asbach, Benedikt ; Kliche, Alexander ; Köstler, Josef ; Perdiguero, Beatriz ; Esteban, Mariano ; Jacobs, Bertram ; Montefiori, David C. ; LaBranche, Celia C. ; Yates, Nicole L. ; Tomaras, Georgia D. ; Ferrari, Guido ; Foulds, Kathryn E. ; Roederer, Mario ; Landucci, Gary ; Forthal, Donald N. ; Seaman, Michael S. ; Hawkins, Natalie ; Self, Steven G. ; Sato, Alicia ; Gottardo, Raphael ; Phogat, Sanjay ; Tartaglia, James ; Barnett, Susan W. ; Burke, Brian ; Cristillo, Anthony D. ; Weiss, Deborah E. ; Francis, Jesse ; Galmin, Lindsey ; Ding, Song ; Heeney, Jonathan L. ; Pantaleo, Giuseppe ; Wagner, Ralf. / Potential to streamline heterologous DNA prime and NYVAC/protein boost HIV vaccine regimens in rhesus macaques by employing improved antigens. In: Journal of Virology. 2016 ; Vol. 90, No. 8. pp. 4133-4149.
@article{747e0cbc94ba4ab1af9b1b396331ca51,
title = "Potential to streamline heterologous DNA prime and NYVAC/protein boost HIV vaccine regimens in rhesus macaques by employing improved antigens",
abstract = "In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus vectors and combinations with DNA and protein vaccines. Earlier clinical trials (EuroVacc trials 01 to 03) evaluated the immunogenicity of HIV-1 clade C GagPolNef and gp120 antigens delivered via the poxviral vector NYVAC. These showed that a vaccination regimen including DNA-C priming prior to a NYVAC-C boost considerably enhanced vaccine-elicited immune responses compared to those with NYVAC-C alone. Moreover, responses were improved by using three as opposed to two DNA-C primes. In the present study, we assessed in nonhuman primates whether such vaccination regimens can be streamlined further by using fewer and accelerated immunizations and employing a novel generation of improved DNA-C and NYVAC-C vaccine candidates designed for higher expression levels and more balanced immune responses. Three different DNA-C prime/NYVAC-C+protein boost vaccination regimens were tested in rhesus macaques. All regimens elicited vigorous and well-balanced CD8+ and CD4+ T cell responses that were broad and polyfunctional. Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and modest antibody-dependent cell-mediated virus inhibition (ADCVI), but very low neutralization activity, were measured after the final immunizations. Overall, immune responses elicited in all three groups were very similar and of greater magnitude, breadth, and quality than those of earlier Euro- Vacc vaccines. In conclusion, these findings indicate that vaccination schemes can be simplified by using improved antigens and regimens. This may offer a more practical and affordable means to elicit potentially protective immune responses upon vaccination, especially in resource-constrained settings.",
author = "Benedikt Asbach and Alexander Kliche and Josef K{\"o}stler and Beatriz Perdiguero and Mariano Esteban and Bertram Jacobs and Montefiori, {David C.} and LaBranche, {Celia C.} and Yates, {Nicole L.} and Tomaras, {Georgia D.} and Guido Ferrari and Foulds, {Kathryn E.} and Mario Roederer and Gary Landucci and Forthal, {Donald N.} and Seaman, {Michael S.} and Natalie Hawkins and Self, {Steven G.} and Alicia Sato and Raphael Gottardo and Sanjay Phogat and James Tartaglia and Barnett, {Susan W.} and Brian Burke and Cristillo, {Anthony D.} and Weiss, {Deborah E.} and Jesse Francis and Lindsey Galmin and Song Ding and Heeney, {Jonathan L.} and Giuseppe Pantaleo and Ralf Wagner",
year = "2016",
month = "4",
day = "1",
doi = "10.1128/JVI.03135-15",
language = "English (US)",
volume = "90",
pages = "4133--4149",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Potential to streamline heterologous DNA prime and NYVAC/protein boost HIV vaccine regimens in rhesus macaques by employing improved antigens

AU - Asbach, Benedikt

AU - Kliche, Alexander

AU - Köstler, Josef

AU - Perdiguero, Beatriz

AU - Esteban, Mariano

AU - Jacobs, Bertram

AU - Montefiori, David C.

AU - LaBranche, Celia C.

AU - Yates, Nicole L.

AU - Tomaras, Georgia D.

AU - Ferrari, Guido

AU - Foulds, Kathryn E.

AU - Roederer, Mario

AU - Landucci, Gary

AU - Forthal, Donald N.

AU - Seaman, Michael S.

AU - Hawkins, Natalie

AU - Self, Steven G.

AU - Sato, Alicia

AU - Gottardo, Raphael

AU - Phogat, Sanjay

AU - Tartaglia, James

AU - Barnett, Susan W.

AU - Burke, Brian

AU - Cristillo, Anthony D.

AU - Weiss, Deborah E.

AU - Francis, Jesse

AU - Galmin, Lindsey

AU - Ding, Song

AU - Heeney, Jonathan L.

AU - Pantaleo, Giuseppe

AU - Wagner, Ralf

PY - 2016/4/1

Y1 - 2016/4/1

N2 - In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus vectors and combinations with DNA and protein vaccines. Earlier clinical trials (EuroVacc trials 01 to 03) evaluated the immunogenicity of HIV-1 clade C GagPolNef and gp120 antigens delivered via the poxviral vector NYVAC. These showed that a vaccination regimen including DNA-C priming prior to a NYVAC-C boost considerably enhanced vaccine-elicited immune responses compared to those with NYVAC-C alone. Moreover, responses were improved by using three as opposed to two DNA-C primes. In the present study, we assessed in nonhuman primates whether such vaccination regimens can be streamlined further by using fewer and accelerated immunizations and employing a novel generation of improved DNA-C and NYVAC-C vaccine candidates designed for higher expression levels and more balanced immune responses. Three different DNA-C prime/NYVAC-C+protein boost vaccination regimens were tested in rhesus macaques. All regimens elicited vigorous and well-balanced CD8+ and CD4+ T cell responses that were broad and polyfunctional. Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and modest antibody-dependent cell-mediated virus inhibition (ADCVI), but very low neutralization activity, were measured after the final immunizations. Overall, immune responses elicited in all three groups were very similar and of greater magnitude, breadth, and quality than those of earlier Euro- Vacc vaccines. In conclusion, these findings indicate that vaccination schemes can be simplified by using improved antigens and regimens. This may offer a more practical and affordable means to elicit potentially protective immune responses upon vaccination, especially in resource-constrained settings.

AB - In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus vectors and combinations with DNA and protein vaccines. Earlier clinical trials (EuroVacc trials 01 to 03) evaluated the immunogenicity of HIV-1 clade C GagPolNef and gp120 antigens delivered via the poxviral vector NYVAC. These showed that a vaccination regimen including DNA-C priming prior to a NYVAC-C boost considerably enhanced vaccine-elicited immune responses compared to those with NYVAC-C alone. Moreover, responses were improved by using three as opposed to two DNA-C primes. In the present study, we assessed in nonhuman primates whether such vaccination regimens can be streamlined further by using fewer and accelerated immunizations and employing a novel generation of improved DNA-C and NYVAC-C vaccine candidates designed for higher expression levels and more balanced immune responses. Three different DNA-C prime/NYVAC-C+protein boost vaccination regimens were tested in rhesus macaques. All regimens elicited vigorous and well-balanced CD8+ and CD4+ T cell responses that were broad and polyfunctional. Very high IgG binding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and modest antibody-dependent cell-mediated virus inhibition (ADCVI), but very low neutralization activity, were measured after the final immunizations. Overall, immune responses elicited in all three groups were very similar and of greater magnitude, breadth, and quality than those of earlier Euro- Vacc vaccines. In conclusion, these findings indicate that vaccination schemes can be simplified by using improved antigens and regimens. This may offer a more practical and affordable means to elicit potentially protective immune responses upon vaccination, especially in resource-constrained settings.

UR - http://www.scopus.com/inward/record.url?scp=84963837923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963837923&partnerID=8YFLogxK

U2 - 10.1128/JVI.03135-15

DO - 10.1128/JVI.03135-15

M3 - Article

VL - 90

SP - 4133

EP - 4149

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 8

ER -